A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

Locally Advanced or Metastatic Solid Tumours Clinical Trial

— DIRECT-01  

Official title:

An Open Labelled First Human Dose Phase 1/2a Study to Evaluate Safety, Feasibility, Efficacy of Multiple Dosing With Individualised VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Clear Renal Cell Carcinoma, Urothelial Cancer or Squamous Cell Carcinoma of Head and Neck, Who Did Not Reach Complete Responses With Current Standard of Care Immune Checkpoint Blockade

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03548467
• Other study ID #: VB N-01
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 4, 2018
• Est. completion date: January 30, 2023

Study information

• Verified date: April 2023
• Source: Nykode Therapeutics ASA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with locally advanced or metastatic solid tumours.

Description:

This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic solid tumours including melanoma, non-small cell lung cancer (NSCLC), clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of the head and neck (SCCHN), who did not reach complete responses with immune checkpoint inhibitor (CPI) therapy as their standard of care (SOC) treatment. Patients with melanoma, NSCLC, RCC and urothelial carcinoma must upon screening, have been receiving a CPI (anti-PD-1 or anti-PD-L1) for at least 12 weeks as the patient's standard of care. Patients with SCCHN can be screened as long as they have initiated treatment with CPI as SOC. The VB10.NEO vaccine will be added to continuing CPI treatment and shall not replace, omit, postpone or terminate the standard therapy. Patients who have been treated with CPI for at least 12 weeks, will be enrolled in case of some benefit to CPI treatment is expected, as defined by partial response, stable disease or disease progression (in case of a mixed response to CPI, provided at least one lesion shows measurable regression and patient, according to the investigator, would have a clinical benefit of continued immunotherapy). The assumption is to combine the immuno-stimulating effect of CPIs with immune responses towards specific neo-antigens in the vaccine, which may possibly increase the anti-tumour effect to reach durable efficacy. One arm of the study patients with SCCHN will have the option to be treated with bempegaldesleukin (NKTR-214) in combination with personalised VB10.NEO. This arm is open for enrollment from November 2019. The study will be conducted in two parts. Part A will evaluate safety, feasibility and efficacy of individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in SCCHN patients. The expansion part B will explore efficacy and safety in further patients with selected types of cancer showing signs of efficacy during part A.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: January 30, 2023
• Est. primary completion date: January 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria for all arms

• Have histologically confirmed locally advanced or metastatic melanoma, NSCLC, RCC, urothelial carcinoma or SCCHN.
• Patients must have been on CPI (i.e., anti-PD-1 or anti PD-L1) for at least 12 weeks before screening and must be on CPI treatment as part of their cancer treatment as prescribed by the treating physician. Inclusion criteria for SCCHN only
• Patients must be on CPI or must initiate treatment with CPI at screening as part of their cancer treatment. All arms
• Patients who have been on CPI for longer than 12 weeks at screening need to be per

RECIST:

• in partial response or;
• stable disease or,
• in progression, i.e., in case of a mixed response to CPI, provided at least one lesion shows measurable regression and who, according to the investigator, have a clinical benefit of continued immunotherapy.
• Adequate tumour specimen must be available for exome sequencing.
• Measurable disease per RECIST 1.1 criteria.
• ECOG performance status = 1.
• Life expectancy at least 6 months in the best judgement of the investigator.
• Willing and able to sign a written informed consent form. Exclusion criteria
• Ocular melanoma.
• Brain metastases (unless controlled and stable for at least 6 weeks) or leptomeningeal spread of disease.
• Positive serological test for hepatitis C virus or hepatitis B virus surface antigen (HBsAg) or human immunodeficiency virus (HIV).
• Other concomitant or prior malignant disease, except for adequately treated basal cell carcinoma or other non-melanomatous skin cancer, low-grade urothelial cancer or other malignancies treated with curative intent within 2 or more years pre-study entry and in complete remission at study entry
• Patients who have an active, known or suspected autoimmune disease. Patients having required systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that require systemic steroids or immunosuppressive agents (Exceptions include any patient on 10 mg or less of prednisolone or equivalent, patients with vitiligo, hypothyroidism stable on hormone replacement; type 1 diabetes, Grave's disease, Hashimoto's disease, alopecia areata, eczema).
• Immunosuppression including the continued use (> 7 days) of high-dose (>10 mg of prednisolone or equivalents) systemic steroids or the use of immunosuppressive agents for any concurrent condition. Other protocol defined inclusion exclusion criteria may apply

Related Conditions & MeSH terms

• Locally Advanced or Metastatic Solid Tumours

Intervention

Biological:
• VB10.NEO
VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).

Drug:
• Bempegaldesleukin
0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.

Locations

Country	Name	City	State
Germany	Charité Research Organisation, Campus Benjamin Franklin	Berlin
Germany	Krankenhaus Nordwest gGmbH	Frankfurt
Germany	Martin-Luther-Universität Halle-Wittenberg, Universitätsklinikum Halle (Saale)	Halle
Germany	University Hospital Heidelberg, NCT, Im Neuenheimer Feld 460	Heidelberg
Germany	Universitätsmedizin Mannheim	Mannheim
Germany	Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie	Munich

Sponsors (3)

Lead Sponsor	Collaborator
Nykode Therapeutics ASA	Nektar Therapeutics, Vaccibody AS

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Adverse Events including SAEs (Safety/tolerability) of VB10.NEO and the combination of VB10.NEO and bempegaldesleukin (NKTR-214)	Total number, severity (CTCAE grade) of adverse events (AEs), and if AE is leading to treatment discontinuation.	Up to 24 months
Secondary	Immunogenicity by T-cell activity to each neoepitope of VB10.NEO and the combination of VB10.NEO and bempegaldesleukin (NKTR-214)	Descriptive analyses for each patient of the immune-response to each neoepiotope	Up to 24 months
Secondary	Objective Response Rate (ORR)	Description of tumor response by iRECIST at regular intervals	Up to 24 months
Secondary	Duration of Response (DOR)	Descriptive analysis of DOR by iRECIST at regular intervals	Up to 24 months
Secondary	Progression-free survival (PFS)	Descriptive analysis of PFS by iRECIST at regular intervals	Up to 24 months
Secondary	Survival at end of treatment (EoT) and end of study (EoS)	Proportion of patients who are alive at EoT and EoS	At 14 months and 24 months